Iptor Set for Future Growth with New Investment and Ownership Structure
Iptor, a leader in distribution and supply chain management, planning and logistics software and services, today announces that it has been acquired by Bregal Unternehmerkapital alongside investment from CEO Jayne Archbold and Chief Marketing and Product Officer Christopher Catterfeld. Bregal Unternehmerkapital is a growth-focused investment firm whose principal focus is to invest behind sound business models and strong leadership teams.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005660/en/
Jayne Archbold (CEO) and Christopher Catterfeld (Chief Marketing and Product Officer) (Photo: Business Wire)
Iptor has been transformed over the past three years under the leadership of Archbold and Catterfeld. The re-branding and re-positioning of the business from IBS to Iptor has delivered exceptional progress, with the product portfolio having been transformed through the successful launch of the aperīo platform. Alongside this a move to micro-services has opened up significant market opportunities in focused verticals with high volume transactions. This has led to more than 150% increase in license and subscription growth in FY18. This has been supported by excellent momentum in the cloud business - by the end of FY19, Iptor will have almost 200 customers on the Power cloud offered through its strategic partnership with IBM.
With the business in great health the scene is now set for the next stage of growth. The investment by Bregal Unternehmerkapital allows Iptor to embark on a ramped-up strategic expansion programme, focusing on building out its leading position in the Technical Wholesale, Pharma and Publishing sectors as well as increasing its geographical footprint and pursuing acquisitions.
Jayne Archbold, Iptor CEO, comments, “We are delighted to make this announcement today and very excited about the future. None of this would be possible without the dedication and passion of our brilliant people as well as our loyal customers. We are excited about the future and the opportunities this creates for our team, our customers and businesses considering partnering with us.”
About Iptor
Iptor is a global leader in enterprise resource planning, supply chain management, planning and logistics software and services. Iptor helps distribution-focused organizations solve their most complex order management and fulfilment challenges within fast-moving, multi-channel and global supply chains, turning them into growth opportunities.
Serving 1,250 customers with 4,000 installations in more than 40 countries, Iptor provides fully integrated enterprise solutions, with highly adaptable and robust software backed by world-class support from distribution and supply chain experts. With its micro-services orientated cloud platforms and the use of smart technologies, Iptor offers compelling value to customers across the Technical Wholesale, Pharma and Publishing sectors. For more information, visit: www.iptor.com.
About Bregal Unternehmerkapital
Bregal Unternehmerkapital is part of COFRA Holding (www.cofraholding.com), a family-owned business that has been built up over generations. Its investment activity is based on long-term commitment and independent of developments in the financial markets. Bregal Unternehmerkapital identifies companies, with strong management teams, that are regarded as market leaders or “hidden champions” in their particular segment. Flexible financing and transaction structures enable it to acquire both minority and majority stakes. In doing so, Bregal Unternehmerkapital is also able to handle complex industry spin-offs, management buy-outs and succession situations. Bregal Unternehmerkapital aims to help companies achieve a sustained improvement in sales and profitability, and provides them with capital, proven financial expertise and access to a broad network of entrepreneurs and industry experts. For more information, visit: www.bregal.de/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005660/en/
Contact information
Ralph Charlton – ralph@charltoncomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release
Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 08:00:00 EEST | Press release
Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers. “Ireland is a leading hub for biopharmaceutical manufacturing and innova
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom